Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology, we’re building an Industry-leading pipeline of wholly-owned drug candidates existing of our nano-ADCs likeTargeted Nanospheres (nADC/TNS).
Last updated on January 12, 2026
Our Investigational Drug Candidates
NanoValent Pharmaceuticals has developed five HPLN (Hybrid Polymerized Liposomal Nanoparticle) based nano-ADCs likeTargeted Nanospheres (nADC/TNS) candidates in oncology.
NV101 (Doxorubicin; anti-CD99)
Validating programs with NV101 in Ewing sarcoma other and CD99 expressing tumors are planned.
NV102 (Doxorubicin; anti-CD19)
Validating programs with NV102 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and other CD19 expressing tumors are planned.
NV103 (Irinotecan; anti-CD99)
NV103, our lead product, is now approaching Investigational News Drug Application (IND) status and is being validated in CD99 expressing tumors, including glioblastoma, ovarian cancer, pancreatic cancer, and Ewing sarcoma.
NV104 (Irinotecan; anti-B7H3)
Validating programs with NV104 in glioblastoma (GBM) and other B7H3 (CD276) expressing tumors are planned.
NV105 (Temozolomide; anti-B7H3)
Validating programs with NV105 in glioblastoma (GBM) and and other B7H3 (CD276) expressing tumors are planned.
NV103, our investigational lead drug candidate, is now approaching U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) status and is being validated in CD99-expressing tumors such as glioblastoma, pancreatic cancer, ovarian cancer, and Ewing sarcoma.
Other validating programs with NV101 in Ewing Sarcoma , NV102, in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and in CD19, CD99 and CD276 (B7H3) expressing tumors are also scheduled.
- Multiple targeting antibodies: CD19, CD99 and CD276 (B7H3) antigens are preferentially express in a wide variety of tumors compared to normal, healthy, tissues
- Multiple payloads: Payloads that have successfully been delivered using our investigational novel format nano-ADCs likeTargeted NanoSpheres (nADC/TNS) include irinotecan, doxorubicin and regulatory RNAs
- Multiple cancer types: At least 75% of common cancers show dramatically improved survival in preclinical PDX mouse models when treated with NV103, our investigational lead nano-ADCs like Targeted Nanospheres (nADC/TNS)
- Combination therapy: In preclinical development, NV103 has shown to be highly effective as a single agent. Because most successful anti-cancer therapies are multi-agent based, we believe that NV103 can be successfully used as part of a combination therapy.
Two encapsulation versions
NV103, our investigational lead drug candidate, utilizes the original aqueous interior nADC/TNS for active loading encapsulation of small molecules like irinotecan. In addition, a second-generation nADC/TNS has a solid cationic lipid interior to capture nucleic acids, with a similar shell to preserve desirable BBB penetration and bioavailability features of TNS.
Preclinical Development
Overall, our novel platform technology promises to enables significant enhancement of the performance of therapeutic agents. For example, in preclinical studies, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted HPLN loaded with Doxorubicin and almost 40 fold versus conventional Doxorubicin.